IQVIA Holdings Inc

IQVIA Holdings Inc(IQV)の株式分析

$262.010

+1.336 (+0.51%)終値時点

Loading chart…
高値
266.660
始値
264.370
出来高加重平均価格
263.16
出来高
1.12M
時価総額
38.76B
安値
260.816
売買代金
294.12M
EV/EBITDA(TTM)
16.01

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others.

ir.iqvia.com

AI分析 of IQVIA Holdings Inc (IQV)

買い

IQVIA Holdings Inc is a good buy right now due to its current price of $259.88, which is below several analyst price targets, including $305 from BofA and $345 from UBS. The company has shown strong revenue growth, with Q2 revenues of $4.37 billion, an 8.7% year-over-year increase, and a solid forward P/E of 18.42, indicating potential for future earnings growth. However, a risk to consider is the insider selling activity, with executives reducing their holdings by 19% and 16%, which may signal caution regarding future performance.

アナリスト評価(17)

-1.41% 下落余地
買い
9 買い
8 中立
0 売り
現在: 262.01
安値
215.00
平均
258.31
高値
290.00

BofA

2026-10-09

目標株価

$305

買い

Mizuho

2026-10-07

目標株価

$300

アウトパフォーム

Barclays

2026-10-07

目標株価

$300

オーバーウェイト

UBS

2026-09-30

目標株価

$345

買い

RBC Capital

2026-09-29

目標株価

$319

アウトパフォーム

バリュエーション指標

IQVIA Holdings Inc(IQV)の現在の予想PERは18.42で、5年平均は18.99です。

予想PER

適正
5年平均 P/E
18.99
現在のP/E
18.42
割高
22.32
割安
15.65

予想EV/EBITDA

割高
5年平均 EV/EBITDA
13.79
現在のEV/EBITDA
16.01
割高
15.92
割安
11.66

予想PSR

適正
5年平均 P/S
2.43
現在のP/S
2.33
割高
2.90
割安
1.95

Alphio AI による IQV の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%IQV

$150.52

シナリオ価格

基

基本

基本 · 50%IQV

$139.87

シナリオ価格

弱

弱気

弱気 · 25%IQV

$124.38

シナリオ価格

IQV を保有するクジラ

H

Howard Capital Management, Inc.

+ を保有IQV

+15.93%

3か月リターン

S

Singapore

+ を保有IQVTSM

+12.33%

3か月リターン

E

Edmond de Rothschild Asset Management (France)

+ を保有IQV

+8.72%

3か月リターン

C

Campbell & Company, LP

+ を保有IQV

+6.70%

3か月リターン

T

Trajan Wealth, L.L.C.

+ を保有IQV

+6.51%

3か月リターン

C

Community Trust and Investment Company

+ を保有IQV

+5.52%

3か月リターン

イベントタイムライン

2026-10-13 (ET)

07:30:00

IQVIA and Veeva Expand Partnership

2026-10-07 (ET)

16:30:00

Iqvia Launches Life Science Models to Predict Clinical Trial Outcomes

16:30:00

Iqvia Launches Iqvia Explorer to Enhance Commercial Decision-Making

2026-09-15 (ET)

09:30:00

The Trade Desk Expands Integrations with Veeva and IQVIA

2026-09-09 (ET)

08:30:00

IQVIA Plans to Raise $2 Billion Through Senior Notes Offering

ニュース

IQV のよくある質問 — Alphio AI が回答

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

IQVIA Holdings Inc is a good buy right now due to its current price of $259.88, which is below several analyst price targets, including $305 from BofA and $345 from UBS. The company has shown strong revenue growth, with Q2 revenues of $4.37 billion, an 8.7% year-over-year increase, and a solid forward P/E of 18.42, indicating potential for future earnings growth. However, a risk to consider is the insider selling activity, with executives reducing their holdings by 19% and 16%, which may signal caution regarding future performance.

17 analysts cover IQV: 9 rate it Buy, 8 Hold and 0 Sell. The average price target is 258.31.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める